The University of Chicago Header Logo

Connection

Peter H. O'Donnell to Patient Compliance

Back to Details
This is a "connection" page, showing publications Peter H. O'Donnell has written about Patient Compliance.
Peter H. O'Donnell
Connection Strength
0.022
Patient Compliance
  1. A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):87-92.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.